PolyPeptide Sets 2026 AGM to Confirm Board and Approve 2025 Reports

PolyPeptide Group AG ( (CH:PPGN) ) has provided an announcement.

PolyPeptide Group AG has published the invitation to its fifth Annual General Meeting, scheduled for 8 April 2026 at the Chollerhalle in Zug, where all six current board members, including Chairman Peter Wilden, will stand for re-election and key committee roles will be confirmed. Shareholders will also vote on the reappointment of auditors and the independent proxy, approve 2025 financial and non-financial reports, and set maximum compensation levels for the board and executive committee, signaling continuity in governance and oversight for the peptide-focused CDMO.

The agenda includes approval of the management report, statutory and consolidated financial statements, as well as the 2025 compensation report in a consultative vote, underscoring the company’s emphasis on transparency in pay and performance alignment. By maintaining its existing board structure and seeking shareholder support for its reporting and compensation framework, PolyPeptide aims to reinforce stability and investor confidence as it pursues growth in the peptide API market.

The most recent analyst rating on (CH:PPGN) stock is a Hold with a CHF24.00 price target. To see the full list of analyst forecasts on PolyPeptide Group AG stock, see the CH:PPGN Stock Forecast page.

More about PolyPeptide Group AG

PolyPeptide Group AG is a specialized global contract development and manufacturing organization focused on peptide-based active pharmaceutical ingredients for pharmaceutical and biotech customers. Serving a fast-growing market from preclinical to commercial stages, it targets therapeutic areas such as metabolic diseases, including GLP-1, through six GMP-certified sites in Europe, the U.S. and India and is listed on SIX Swiss Exchange.

Average Trading Volume: 71,830

Technical Sentiment Signal: Sell

Current Market Cap: CHF806M

Learn more about PPGN stock on TipRanks’ Stock Analysis page.